Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375688 | 0.91 | TTK (0.84) | TTK | |
| SCHEMBL9941202 | 0.89 | TTK (0.86) | TTK | |
| SCHEMBL15375681 | 0.88 | TTK (1.00) | TTK | |
| SCHEMBL15375695 | 0.87 | TTK (1.00) | TTK | |
| SCHEMBL12986591 | 0.86 | TTK (1.00) | TTK | |
| SCHEMBL15375743 | 0.86 | TTK (0.82) | TTK | |
| SCHEMBL9937496 | 0.86 | TTK (0.89) | TTK | |
| SCHEMBL15375728 | 0.86 | TTK (0.79) | TTK | |
| SCHEMBL15384821 | 0.86 | TTK (0.82) | TTK | |
| SCHEMBL9942817 | 0.86 | TTK (0.75) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4527946-A1 | METHOD FOR PREDICTING THE RESPONSE TO A DUAL SPECIFICITY PROTEIN KINASE TTK INHIBITOR THERAPY | Pangaea Oncology, S.A (ES) | 2025-03-26 | — | — | EP | claimed |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-14 | — | — | US | claimed |
| EP-4527946-A1 | METHOD FOR PREDICTING THE RESPONSE TO A DUAL SPECIFICITY PROTEIN KINASE TTK INHIBITOR THERAPY | Pangaea Oncology, S.A (ES) | 2025-03-26 | — | — | EP | disclosed |
| US-12133892-B2 | Methods and compositions for increasing susceptibility to radiation treatment by inhibiting suppression of numerical chromosomal instability of cancer cells | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-11-05 | — | — | US | disclosed |
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| US-12054784-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-06 | — | — | US | disclosed |
| EP-3283642-B1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RES CENTER HOLDING B V (NL) | 2023-10-11 | — | — | EP | disclosed |
| EP-3283642-B1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RES CENTER HOLDING B V (NL) | 2023-10-11 | — | — | EP | disclosed |
| US-20230293693-A1 | METHODS AND COMPOSITIONS FOR INCREASING SUSCEPTIBILITY TO RADIATION TREATMENT BY INHIBITING SUPPRESSION OF NUMERICAL CHROMOSOMAL INSTABILITY OF CANCER CELLS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-09-21 | — | — | US | disclosed |
| US-11623006-B2 | Methods and compositions for increasing susceptibility to radiation treatment by inhibiting suppression of numerical chromosomal instability of cancer cells | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-04-11 | — | — | US | disclosed |
| CN-114592061-A | Prognostic biomarkers for TTK inhibitor chemotherapy | 荷兰转化研究中心有限责任公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20180112258-A1 | MEDICAL USES AND METHODS FOR TREATING CANCER USING MONOPOLAR SPINDLE 1 (MPS1) KINASE INHIBITORS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2018-04-26 | — | — | US | disclosed |
| EP-3247410-A2 | METHODS AND COMPOSITIONS FOR INCREASING SUSCEPTIBILITY TO RADIATION TREATMENT BY INHIBITING SUPPRESSION OF NUMERICAL CHROMOSOMAL INSTABILITY OF CANCER CELLS | Memorial Sloan-Kettering Cancer Center (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016166255-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016130297-A2 | METHODS AND COMPOSITIONS FOR INCREASING SUSCEPTIBILITY TO RADIATION TREATMENT BY INHIBITING SUPPRESSION OF NUMERICAL CHROMOSOMAL INSTABILITY OF CANCER CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2016-08-18 | — | — | WO | disclosed |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| EP-2651948-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080229-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | TK1, CDKL1, CDK1 | TTK 136/4885 |
| US-12054784-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | TTBK1, CTNNB1, TTK | TTK 3/4885 |
| US-20180112258-A1 | MEDICAL USES AND METHODS FOR TREATING CANCER USING MONOPOLAR SPINDLE 1 (MPS1) KINASE INHIBITORS | BUB1B, BUB1, AURKC | TTK 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.